Phytopharm obesity drug suffers setback
Thursday 31 July 2003
Phytopharm, the company trying to develop drugs from plant extracts, suffered a big setback yesterday when Pfizer - the biggest drug company in the world - abandoned work on its much-hyped treatment for obesity.
The news wiped a third off Phytopharm's market value, although the ebullient chief executive, Richard Dixey, argued the drug would still get to market, and the delay could even improve the company's future profitability.
The drug development project, codenamed P57, is based on a Kalahari desert cactus, known as a Hoodia, which has been used for centuries as an appetite suppressant by the San people in southern Africa.
Pfizer had been preparing to launch a final stage of human trials in the autumn, but has been cutting back work on natural medicines in the wake of its $260bn merger with Pharmacia.
Mr Dixey argued that the stock market reaction - sending the shares down 85p to 175p - was ill-judged. "The drug has been returned to us because of a restructuring within Pfizer, not because it has failed, and any reaction of the share price has to be looked at in that light."
Pfizer signed up in 1988 to work on P57 and had been funding much of the development. Its decision to abandon the project and hand back the rights to the product to Phytopharm robs the UK company of the prospect that the world's biggest drug salesforce will be marketing its drug. More immediately, it means a $2m milestone payment will not come in as expected in the autumn.
Mr Dixey said that "seven of the top 10 multinationals" had previously expressed an interest in P57 and he was confident of finding a new partner. "We are now able to open up the doors and we hope to begin that process very shortly. We hope to have concluded that work by the half-year and if we do so this could actually be cash-positive rather than cash-neutral."
He argued that positive results from the human trials conducted by Pfizer to date should allow Phytopharm to get a better deal from a new licensee than it got from Pfizer in 1988.
Shares in Phytopharm are back only to their levels of three months ago, before a Panorama documentary on the San, featuring Mr Dixey, who is a buddhist, reignited stock market interest. The stock has been an erratic performer, peaking as high as 880p in 2001, but tumbling back after one of the company's most-hyped products, a treatment for baldness, turned out to be less effective than E45 moisturising cream. There was also hilarity when its treatment for arthritis in dogs made their coats smell of urine.
- 1 Migrant crisis: Greek soldier saved 20 people singlehandedly off Rhodes beach
- 2 Sofyen Belamouadden murder: The inside story of a crime that horrified Britain
- 3 UK weather: Britain braced for snow as arctic air mass moves in
- 5 'Isis' schoolgirls: Missing British teenager tweets picture of her Syrian takeaway
Migrant crisis: Greek soldier saved 20 people singlehandedly off Rhodes beach
Ian Brady: Moors murderer announces his support for Ukip and the SNP
Aaron and Melissa Klein: Oregon anti-gay bakers ordered to pay $135,000 after refusing to make cake for same-sex wedding
UK weather: Britain braced for snow as arctic air mass moves in
Power of Nepal earthquake was equivalent to 20 huge atomic bombs
General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband
The sickening truth about food banks that the Tories don't want you to know
Migrant boat disaster: Ukip candidate mocks victims in sickening Twitter post
Nigel Farage wants the BBC to stop making programmes like Doctor Who, Strictly Come Dancing, and Top Gear
Global warming: Scientists say temperatures could rise by 6C by 2100 and call for action ahead of UN meeting in Paris
General Election 2015: Britain would become a 'communist dictatorship' under Ed Miliband and Nicola Sturgeon, claims wife of Michael Gove
iJobs Money & Business
£20000 - £60000 per annum: Recruitment Genius: Are you recently QCA Level 4 qu...
£20000 - £22500 per annum + OTE £30K: SThree: SThree Group have been well esta...
£25 - 30k: Guru Careers: We are seeking an Application Support Analyst / 1st L...
£45K - £55K (DOE) + Benefits: Guru Careers: We are seeking a full stack .NET D...